Gut microbiota and metabolite profiles in HBV cirrhosis with persistent liver enzyme abnormalities
Frontiers in Microbiology · 10.10.2025 · 16
DOI: 10.3389/fmicb.2025.1645023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 10.10.2025. Verfasst von Huan He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims Dysbiosis of gut microbiota and metabolic disturbances are implicated in the progression of hepatitis B virus (HBV)-related cirrhosis. However, the mechanisms underlying these associations, particularly in patients with undetectable HBV-DNA following antiviral therapy but persistent liver enzyme abnormalities, remain poorly understood. This study aimed to characterize the gut microbiota and metabolic profiles in this patient population to elucidate potential mechanisms and identify biomarkers. Materials and methods Sixty-five patients with HBV-related cirrhosis were enrolled. Fecal samples were analyzed using 16S rRNA gene sequencing and untargeted liquid chromatography-mass spectrometry (LC–MS) to assess gut microbiota composition and metabolite profiles. Correlation analyses and multivariate statistical approaches were employed to explore relationships between microbiota, metabolites, and clinical parameters.
Results
Significant gut microbiota dysbiosis was observed in HBV-related cirrhosis patients. Comparative analysis identified 15 differentially abundant genera and 431 metabolites between patients with normal and abnormal liver enzyme levels. Notably, Blautia abundance was positively correlated with ursocholic acid (UCA), which was significantly reduced in patients with abnormal liver enzymes. UCA levels were inversely associated with AST, TBIL, and ALP, suggesting its potential role in modulating liver enzyme activity.
Conclusion
These findings highlight the gut-liver axis as a driver of persistent liver injury and identify microbial (e.g., Blautia) and metabolic (e.g., UCA, TDC) signatures as potential biomarkers for HBV cirrhosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongq…
Zitieren
APA
He, H., Zou, R., Liao, X., & Lan, Y. (2025). Gut microbiota and metabolite profiles in HBV cirrhosis with persistent liver enzyme abnormalities. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1645023
Vancouver
He H, Zou R, Liao X, Lan Y. Gut microbiota and metabolite profiles in HBV cirrhosis with persistent liver enzyme abnormalities. Frontiers in Microbiology. 2025;16. doi:10.3389/fmicb.2025.1645023
BibTeX
@article{He2025,
author = {He, Huan and Zou, Ruixue and Liao, Xinyi and Lan, Yinghua},
title = {Gut microbiota and metabolite profiles in HBV cirrhosis with persistent liver enzyme abnormalities},
journal = {Frontiers in Microbiology},
year = {2025},
volume = {16},
doi = {10.3389/fmicb.2025.1645023}
}
EUVIMED